Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 4, 2025
Finance
Isomorphic’s $600M funding among four megarounds: Finance Report
Other nine-digit financings go to Airna, Atsena, Neurona
BioCentury | Mar 12, 2025
Product Development
Oral peptide win for Protagonist/J&J, Beam’s base editor POC, and more: Clinical Report
Protagonist data led to week’s biggest share price gain, while Arvinas saw biggest loss: in BioCentury’s latest Clinical Report
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Oct 22, 2024
Finance
Venture funds, a new chapter for MS & Wave’s data: a BioCentury podcast
What Forbion’s $2.2B raise says about the state of venture, NIH’s Daniel Reich on MS and RNA-editing oligo data from Wave
BioCentury | Oct 17, 2024
Product Development
Wave data propel RNA-editing stocks, but are all platforms created equal?
In first human RNA-editing data, Wave reports positive results from WVE-006 in alpha-1 antitrypsin deficiency
BioCentury | Apr 12, 2024
Deals
In $4.9B Alpine deal, Vertex sees best-in-class therapy with room for label expansions
Buyer believes povetacicept can outshine others in BAFF/APRIL class, even if not first to market — and can become a pipeline-in-a-product
BioCentury | Jan 23, 2024
Deals
Sanofi gets clinical AAT therapy via takeout-and-spinout deal with Inhibrx
Echoing Biohaven’s arrangement with Pfizer, most Inhibrx assets will land in a well-capitalized newco
BioCentury | Sep 20, 2023
Finance
Sept. 19 Quick Takes: RNA editing company Airna emerges with $30M round led by Arch
Plus: Longevity-focused VC debuts and updates from Recode, Merck, Taysha and Paratek
BioCentury | Jul 15, 2023
Deals
July 14 Quick Takes: Korro heads to NASDAQ via reverse merger
Plus: Theseus abandons GIST therapy, Roche-Roivant rumors
BioCentury | Sep 17, 2022
Product Development
HAE data clear Intellia’s path for liver knockout indications
The next test for Intellia will be whether it can achieve the same success with gene insertions
Items per page:
1 - 10 of 120